New data boosts our confidence in Lilly's obesity pill. Plus, Google's new AI features

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets are slightly lower on Tuesday, with the S & P 500 on pace for its third down session in a row. For most of the session, there was a rotation out of AI buildout names into software , but it lost steam as the day progressed and reversed. For example, Salesforce was up around $8 per share to $187 before turning negative on the day. The main story in the market right now is all about interest rates. With energy prices stubbornly high due to uncertainty around the Strait of Hormuz and Iran war, fears of inflation are rippling through the bond market. The climb in Treasury yields continued, with the 10-year yield jumping to 4.665% and the 30-year yield hitting 5.19%, its highest level in almost 19 years. Rising rates and high energy prices can hurt consumer spending and slow the economy ( Home Depot's lackluster results are a good example of this), hence the buying Tuesday of defensive, non-cyclical names like healthcare. Eli Lilly shares have additional reason to be higher, adding over 2%. In a note to clients Tuesday, analysts at Citigroup published positive findings from their survey of oral GLP-1 physicians. Some of the big takeaways we already knew. …